HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Götze, K. S. Articles by Decker, T. Search for Related Content PubMed PubMed Citation Articles by Götze, K. S. Articles by Decker, T.

Fatal Epstein-Barr virus-associated lymphoproliferative disorder following treatment with a novel mTOR Inhibitor for relapsed chronic lymphocytic leukemia

^* III. Department of Medicine,
^° Institute of Virology
^# Institute for Pathology, Technical University of Munich, Munich, Germany

Correspondence: Katharina S. Götze, MD, III. Department of Medicine, Technical University of Munich, Ismaningerstrasse 15, 81675 Munich, Germany. Phone: international +49.89.41406318. Fax: international +49.89.4140-4826. E-mail: k.goetze{at}lrz.tum.de

We report on a patient with relapsed chronic lymphocytic leukemia (CLL) treated with the novel mTOR inhibitor RAD001 within a phase II clinical trial. Although the patient initially responded to therapy, RAD001 was discontinued after 32 weeks due to progression and fludarabine-based chemotherapy was started. The patient subsequently developed a rapidly fatal Epstein-Barr-virus-associated lymphoproliferative disorder, clonally unrelated to the CLL. The clinical course suggests caution when using newer immunosuppressive drugs for treatment of CLL, especially in the context of additional purine analog therapy.

Key words: CLL, mTOR, EBV, RAD001, lymphoproliferative disorder.